Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation

Takeda37 enrolled

Overview

The purpose of this study is to explore the effects of omega-3-acid ethyl esters (TAK-085) on vascular endothelial function when administered for 8 weeks, as measured by FMD, in patients with hyperlipidemia.

This is a multicenter, collaborative, randomized, open-label study designed to explore the effects of administration of omega-3-acid ethyl esters (TAK-085) \[2 g (2 g PO QD) or 4 g (2 g PO BID) for 8 weeks\] on vascular endothelial function, as measured by flow-mediated dilation (FMD), in patients receiving a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and have concurrent hypertriglyceridemia. Considering the potential bias by factors that affect FMD between treatment groups, stratified allocation will be performed with fasting triglyceride (TG) level as a factor.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Hyperlipidemia

Interventions

TAK-085DRUG

TAK-085 capsules

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Participants with the diagnosis of hyperlipidemia and receiving instructions for lifestyle improvement 2. Participants with a fasting TG level of 150 -499 mg/dL at Visit 1 after informed consent (Day -29 to Day -1 before start of study drug administration) 3. Participants receiving a stable dose of HMG-CoA reductase inhibitor therapy continuously for at least 4 weeks before informed consent at Visit 1 (Day -29 to Day -1 before start of study drug administration) 4. Male or postmenopausal female participants 5. Participants who, in the opinion of the principal investigator or the investigator, are capable of understanding the content of the clinical research and complying with the research protocol requirements. 6. Participants who can provide written informed consent prior to the conduction of the clinical research procedures 7. Participants aged ≥20 years at the time of informed consent at Visit 1(Day -28 to Day 0 before the start of study drug administration) Exclusion Criteria: 1. Participants with a history of revascularization or those have had coronary artery disease (a definitive diagnosis of myocardial infarction, angina) within 24 weeks before informed consent at Visit 1 (Day -29 to Day -1 before the start of study drug administration) 2. Participants who have undergo aortic aneurysmectomy within 24 weeks prior to informed consent at Visit 1 (Day -29 to Day -1 before the start of study drug administration) or those with concurrent aortic aneurysm 3. Participants who have had clinically significant hemorrhagic disorders (e.g., hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, and vitreous hemorrhage) within 24 weeks prior to informed consent at Visit 1 (Day -29 to Day -1 before the start of study drug administration) or those who concurrently have the above disorders 4. Participant with a fasting FMD level of 0% measured at the start of study drug administration at Visit 2 (Day -15 to Day -1 before the start of study drug administration) 5. Participants in whom the type and dosage of HMG-CoA reductase inhibitors, antidiabetic drugs and antihypertensive drugs have been changed within 4 weeks prior to informed consent at Visit 1 (Day -29 to Day -1 before the start of study drug administration) 6. Participants who have started anti dyslipidemic agents within 4 weeks prior to informed consent at Visit 1 (Day -29 to Day -1 before the start of study drug administration) 7. Participants requiring a change in the dose of dyslipidemia therapeutic, antidiabetic, or antihypertensive drugs during the period between informed consent at Visit 1 (Day -29 to Day -1 before the start of study drug administration) and the start of study drug administration at Visit 2 (Day -15 to Day -1 before the start of study drug administration) 8. Participants with severe hepatic dysfunction 9. Participants with severe renal dysfunction (as an indicator, CKD category ≥G3b, equivalent to an A3) 10. Participants who have been diagnosed with pancreatitis 11. Participants who have been diagnosed with lipoprotein lipase deficiency, apoprotein C-II deficiency, familial hypercholesterolemia, familial combined hyperlipidemia, or familial type III hyperlipidemia 12. Participants with concurrent Cushing's syndrome, uremia, systemic lupus erythematosus (SLE), serum dysproteinemia, or hypothyroidism 13. Participants with symptomatic Peripheral Arterial Disease (PAD) 14. Participants with concurrent hypertension of grade II or higher Note 1) Note 1: Participants with systolic blood pressure of ≥160 mm Hg or diastolic BP of ≥100 mm Hg regardless of treatment with antihypertensive drugs 15. Participants who are habitual drinkers drinking an average of over 100 mL per day (expressed in terms of quantity of alcohol) or participants with, or with a history of drug abuse or addiction Note 2) 16. Participants with a history of hypersensitivity or allergy for omega-3-acid ethyl esters- 17. Participants who smoke 18. Participants participating in other clinical studies 19. Participants who have been determined to be ineligible as subjects in the study by the principal investigator or the investigator

Locations (4)

Unnamed facility

Yufu, Oita Prefecture, Japan

Unnamed facility

Shinjuku, Tokyo, Japan

Unnamed facility

Kagoshima, Japan

Unnamed facility

Ōita, Japan

Outcomes

Primary Outcomes

Flow-mediated Dilation (FMD) With Fasting State at Baseline, Week 4 and Week 8

FMD refers to dilation (widening) of an artery when blood flow increases in that artery. To determine FMD, brachial artery dilation following a transient period of forearm ischemia is measured using ultrasound. FMD was calculated by the value of Maximum diastolic vessel size minus vessel size at rest, divided by vessel size at rest, described with percentage.

Time frame: Prior to meal at Baseline, Week 4, and Week 8

Change From Baseline in FMD With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in FMD With Fasting State at Baseline, Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Secondary Outcomes

FMD With 4-Hours Postprandial State at Baseline and Week 8

Time frame: 4-hours after meal at Baseline and Week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Change From Baseline in FMD With 4-Hours Postprandial State at Week 8

Time frame: 4-hours after meal at Baseline and Week 8

Percent Change From Baseline in FMD With 4-Hours Postprandial State at Week 8

Time frame: 4-hours after meal at Baseline and Week 8

Triglyceride (TG) Level With Fasting State at Baseline, Week 4, and Week 8

Time frame: Prior to meal at Baseline, Week 4, and Week 8

Change From Baseline in TG Level With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in TG Level With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

TG Level With 4-Hours Postprandial State at Baseline, Week 4 and Week 8

Time frame: 4-hours after meal at Baseline, Week 4, and Week 8

Change From Baseline in TG Level With 4-Hours Postprandial State at Week 4 and Week 8

Time frame: 4-hours after meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in TG Level With 4-Hours Postprandial State at Week 4 and Week 8

Time frame: 4-hours after meal at Baseline and Week 4, and Week 8

Dihomo-gamma-linolenic Acid Concentration With Fasting State at Baseline, Week 4 and Week 8

Samples for plasma fatty acid fractions (Dihomo-gamma-linolenic acid, Arachidonic acid, Eicosapentaenoic acid, Docosahexaenoic acid, EPA/AAratio, and DHA/AAratio) were taken under the fasting condition. Reported data was the observation value at each point.

Time frame: Prior to meal at Baseline, Week 4 and Week 8

Change From Baseline in Dihomo-gamma-linolenic Acid Concentration With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in Dihomo-gamma-linolenic Acid Concentration With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Arachidonic Acid Concentration With Fasting State at Baseline, Week 4 and Week 8

Time frame: Prior to meal at Baseline, Week 4 and Week 8

Change From Baseline in Arachidonic Acid Concentration With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in Arachidonic Acid Concentration With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Eicosapentaenoic Acid Concentration With Fasting State at Baseline, Week 4 and Week 8

Time frame: Prior to meal at Baseline, Week 4 and Week 8

Change From Baseline in Eicosapentaenoic Acid Concentration With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in Eicosapentaenoic Acid Concentration With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Docosahexaenoic Acid Concentration With Fasting State at Baseline, Week 4 and Week 8

Time frame: Prior to meal at Baseline, Week 4 and Week 8

Change From Baseline in Docosahexaenoic Acid Concentration With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in Docosahexaenoic Acid Concentration With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Eicosapentaenoic Acid to Arachidonic Acid (EPA/AA) Ratio With Fasting State at Baseline, Week 4 and Week 8

Time frame: Prior to meal at Baseline, Week 4 and Week 8

Change From Baseline in EPA/AA Ratio With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in EPA/AA Ratio With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Docosahexaenoic Acid to Arachidonic Acid (DHA/AA) Ratio With Fasting State at Baseline, Week 4 and Week 8

Time frame: Prior to meal at Baseline, Week 4 and Week 8

Change From Baseline in DHA/AA Ratio With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Percent Change From Baseline in DHA/AA Ratio With Fasting State at Week 4 and Week 8

Time frame: Prior to meal at Baseline and Week 4, and Week 8

Number of Participants Reporting One or More Adverse Events (AEs)

Time frame: Up to Week 8

Number of Participants Reporting One or More AEs Related to Body Weight

Time frame: Up to Week 8

Number of Participants Reporting One or More AEs Related to Blood Pressure in the Sitting Position

Time frame: Up to Week 8

Number of Participants Reporting One or More AEs Related to Pulse in the Sitting Position

Time frame: Up to Week 8

Number of Participants Reporting One or More AEs Related to Laboratory Tests of Fasting Plasma Glucose

Time frame: Up to Week 8